1. Home
  2. CERO vs RDHL Comparison

CERO vs RDHL Comparison

Compare CERO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • RDHL
  • Stock Information
  • Founded
  • CERO 2017
  • RDHL 2009
  • Country
  • CERO United States
  • RDHL Israel
  • Employees
  • CERO N/A
  • RDHL N/A
  • Industry
  • CERO
  • RDHL Biotechnology: Pharmaceutical Preparations
  • Sector
  • CERO
  • RDHL Health Care
  • Exchange
  • CERO Nasdaq
  • RDHL Nasdaq
  • Market Cap
  • CERO 8.4M
  • RDHL 8.2M
  • IPO Year
  • CERO N/A
  • RDHL N/A
  • Fundamental
  • Price
  • CERO $1.92
  • RDHL $5.85
  • Analyst Decision
  • CERO
  • RDHL
  • Analyst Count
  • CERO 0
  • RDHL 0
  • Target Price
  • CERO N/A
  • RDHL N/A
  • AVG Volume (30 Days)
  • CERO 787.1K
  • RDHL 11.1K
  • Earning Date
  • CERO 02-20-2025
  • RDHL 04-07-2025
  • Dividend Yield
  • CERO N/A
  • RDHL N/A
  • EPS Growth
  • CERO N/A
  • RDHL N/A
  • EPS
  • CERO N/A
  • RDHL N/A
  • Revenue
  • CERO N/A
  • RDHL $3,707,000.00
  • Revenue This Year
  • CERO N/A
  • RDHL $224.90
  • Revenue Next Year
  • CERO N/A
  • RDHL $82.69
  • P/E Ratio
  • CERO N/A
  • RDHL N/A
  • Revenue Growth
  • CERO N/A
  • RDHL N/A
  • 52 Week Low
  • CERO $1.76
  • RDHL $5.41
  • 52 Week High
  • CERO $1,238.00
  • RDHL $20.28
  • Technical
  • Relative Strength Index (RSI)
  • CERO 34.43
  • RDHL 40.41
  • Support Level
  • CERO $1.76
  • RDHL $5.80
  • Resistance Level
  • CERO $3.18
  • RDHL $6.26
  • Average True Range (ATR)
  • CERO 0.38
  • RDHL 0.31
  • MACD
  • CERO 0.30
  • RDHL 0.01
  • Stochastic Oscillator
  • CERO 19.72
  • RDHL 19.33

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

Share on Social Networks: